

consistent with maintenance of effective controls against diversion solely because a smaller number is capable of producing an adequate and uninterrupted supply.

DEA is confident that the registration of Johnson Matthey will not impede DEA's statutory obligation to guard against the diversion of controlled substances.

Also, with respect to the second commentor's allegation that John Matthey has a huge capability and experience gap, Johnson Matthey has been registered with DEA since 1985. In the past 11 years, Johnson Matthey has demonstrated its technical and manufacturing expertise with respect to other controlled substances. Based on this history and recent investigation, DEA is confident that Johnson Matthey will continue this practice with respect to the opiates.

Additionally, DEA has investigated Johnson Matthey on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. The results of these investigations have led DEA to conclude that Johnson Matthey is in compliance with the CSA and that its continued registration is consistent with the public interest.

The third commentor states that there is sufficient information to show that the registration of Johnson Matthey to bulk manufacture methylphenidate is not in the public interest and an order to show cause be issued to deny Johnson Matthey's application.

However, in Federal Register notice 61 FR 46664 (September 4, 1996), it was ordered that a request for a hearing concerning Johnson Matthey's February 1995, registration application and the proceedings following and relevant to that request be, and they hereby are, terminated. Since the ALJ approved Johnson Matthey's 1992 application to bulk manufacture methylphenidate on September 29, 1994, as a result of a previous hearing and the hearing request for the 1995 application was terminated, DEA finds no basis for yet another hearing to deny Johnson Matthey's application to bulk manufacture methylphenidate.

After reviewing all the evidence, including the comments filed, DEA has determined, pursuant to 21 U.S.C. 823(a), that registration of Johnson Matthey as a bulk manufacturer of

oxycodone, hydrocodone, dihydrocodeine, oxymorphone, thebaine and methylphenidate is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator hereby orders that the 1996 applications submitted by Johnson Matthey for registration as a bulk manufacturer of the listed controlled substances, excluding codeine and morphine, but including oxycodone, hydrocodone, dihydrocodeine, oxymorphone, thebaine and methylphenidate are granted.

Dated: December 12, 1996.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 96-32612 Filed 12-23-96; 8:45 am]
BILLING CODE 4410-09-M

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 21, 1996, and published in the Federal Register on September 5, 1996, (61 FR 46827), Noramco of Delaware, Inc., Division of McNeilab, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application for renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Codeine (9050)	II
Oxycodone (9143)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Thebaine (9333)	II

By a Notice of Correction dated October 21, 1996, and published in the Federal Register on November 14, 1996, (61 FR 58424), fentanyl was deleted from Noramco of Delaware, Inc.'s application for bulk manufacture.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Noramco of Delaware, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 C.F.R. 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled

substances listed above is granted, except for fentanyl.

Dated: December 5, 1996.
Gene R. Haislip,
Deputy Assistant Administrator Office of Diversion Control Drug Enforcement Administration.
[FR Doc. 96-32606 Filed 12-23-96; 8:45 am]
BILLING CODE 4410-09-M

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 2, 1996, Radian International LLC, 8501 North Mopac Blvd., P.O. Box 201088, Austin, Texas 78720, made application by letter dated October 2, 1996, to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Alpha-Ethyltryptamine (7249)	I
3,4,5-Trimethoxyamphetamine (7390)	I
4-Bromo-2,5-dimethoxyamphetamine (7391)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I
4-Methyl-2,5-dimethoxyamphetamine (7395)	I
2,5-Dimethoxyamphetamine (7396)	I
2,5-Dimethoxy-4-ethylamphetamine (7399)	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I
Bufotenine (7433)	I
Codeine-N-oxide (9053)	I
Heroin (9200)	I
Morphine-N-oxide (9307)	I
Pholcodine (9314)	I
Alphamethadol (9605)	I
Betcetylmethadol (9607)	I
Betamethadol (9609)	I
Norlevorphanol (9634)	I
Para-Fluorofentanyl (9812)	I
Alpha-methylfentanyl (9814)	I
Acetyl-alpha-methylfentanyl (9815)	I
Beta-hydroxyfentanyl (9830)	I
Beta-hydroxy-3-methylfentanyl (9831)	I
Alpha-Methylthiofentanyl (9832)	I
3-Methylthiofentanyl (9833)	I
Thiofentanyl (9835)	I
Phenmetrazine (1631)	II
Glutethimide (2550)	II
Cocaine (9041)	II
Codeine (9050)	II
Levomethorphan (9210)	II